ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Regulatory considerations in technology for decentralised clinical trials
This article explores the guidance regulators have provided for diversity and inclusion in clinical trials, privacy considerations and endpoint selection.
Bioanalytical outsourcing soars as drugs grow more complex
In this article, Radboud van Trigt looks at trends in bioanalytic outsourcing against the backdrop of the increasingly complex nature of modern-day therapeutics.
Moving closer to dynamic drug development
Dr. Ute Berger looks at how novel solutions and improvements aimed at benefitting the drug development process with the right framework are coming to the fore.
Endpoints News LGBTQ+ Biopharma Leaders '23
Find more about the scientists, executives, founders and academics who are leading the way for LGBTQ+ inclusion in the drug development industry.
Disease surveillance and vaccine development
In this article in Life Science Review, Dinah Knotts outlines how disease surveillance can play an important role in emerging infectious disease early.
Realising the benefits of bringing the trial to the patient
This article outlines how in-home services are being baked into trials because of their value in supporting patient-centric trials with decentralised components.
The most explored endpoints in decentralised clinical trials
Harpreet Gill and Keith Thomas contribute to this article that investigates decentralisation from the perspective of trial endpoints or outcome measures.
Transfer of marketing authorisation
In this interview, Alma Salibasic, discusses the role of a Marketing Authorisation Transfer during mergers and acquisitions in the bio pharma industry.
Interview: Everything you need to know about becoming a clinical research associate
In this interview, Sara Brannon, Director of Quality and Training Development at ICON, shares the approach to recruiting clinical research associates.
Challenges of expanding CAR-T Cell Therapy into solid tumors
Read more about the challenges in developing CAR-T therapies for solid tumors in this article.